Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

ITCI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.60%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $44,873,863.99

Intra-Cellular Therapies Insider Trading History Chart

Intra-Cellular Therapies Share Price & Price History

^$90.51

▲ +1.07 (1.20%)

As of 11/7/2024 01:00 AM ET

Days: 30 | 90 | 365

625,000% Gain

From Crypto Swap Profits | Ad

>> Dive into the Workshop Here

Intra-Cellular Therapies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/30/2024	Sharon Mates	CEO	Sell	34,396	$72.84	$2,505,404.64	1,070,329
8/27/2024	Sharon Mates	CEO	Sell	40,513	$73.58	$2,980,946.54	1,070,329
8/23/2024	Sharon Mates	CEO	Sell	28,680	$74.46	$2,135,512.80	1,070,329
8/21/2024	Sharon Mates	CEO	Sell	53,013	$75.65	$4,010,433.45	1,070,329
8/16/2024	Mark Neumann	EVP	Sell	18,714	$75.08	$1,405,047.12	29,700
6/24/2024	Rory B. Riggs	Director	Sell	4,462	$75.57	$337,193.34	116,600
6/18/2024	Robert L. Van Nostrand	Director	Sell	20,000	$75.91	$1,518,200.00	9,690
3/11/2024	Lawrence J. Hineline	CFO	Sell	10,121	$65.96	$667,581.16
3/11/2024	Michael Halstead	EVP	Sell	7,345	$65.97	$484,549.65	19,803
3/11/2024	Sharon Mates	CEO	Sell	20,565	$65.21	$1,341,043.65	1,050,309
3/7/2024	Lawrence J. Hineline	CFO	Sell	13,132	$66.60	$874,591.20	29,700
3/7/2024	Sharon Mates	CEO	Sell	40,712	$66.50	$2,707,348.00	1,050,309
3/7/2024	Suresh K. Durgam	EVP	Sell	6,450	$66.56	$429,312.00	16,170
2/26/2024	Joel S. Marcus	Director	Sell	26,328	$68.68	$1,808,207.04	39,662
2/26/2024	Lawrence J. Hineline	CFO	Sell	13,337	$69.43	$925,987.91
2/26/2024	Michael Halstead	EVP	Sell	7,907	$69.53	$549,773.71	29,700
2/26/2024	Sharon Mates	CEO	Sell	22,590	$69.79	$1,576,556.10	1,050,309
1/18/2024	Sharon Mates	CEO	Sell	67,917	$65.19	$4,427,509.23	1,050,309
1/16/2024	Sharon Mates	CEO	Sell	75,361	$67.25	$5,068,027.25	1,050,309
1/11/2024	Michael Halstead	EVP	Sell	50,000	$66.83	$3,341,500.00
1/2/2024	Suresh K. Durgam	EVP	Sell	62,282	$70.60	$4,397,109.20
12/13/2023	Suresh K. Durgam	EVP	Sell	21,262	$65.00	$1,382,030.00
11/6/2023	Mark Neumann	EVP	Sell	42,393	$55.63	$2,358,322.59	29,700
9/18/2023	Sharon Mates	CEO	Sell	55,587	$53.76	$2,988,357.12	1,094,722
8/7/2023	Mark Neumann	EVP	Sell	55,300	$58.79	$3,251,087.00	45,339
7/17/2023	Suresh K. Durgam	EVP	Sell	1,842	$65.00	$119,730.00	21,262
6/14/2023	Lawrence J. Hineline	CFO	Sell	81,854	$63.97	$5,236,200.38
4/17/2023	Robert L. Van Nostrand	Director	Sell	10,000	$63.00	$630,000.00	9,345
3/28/2023	Mark Neumann	EVP	Sell	15,604	$54.31	$847,453.24	45,339
3/13/2023	Lawrence J. Hineline	CFO	Sell	5,582	$44.93	$250,799.26
3/13/2023	Sharon Mates	CEO	Sell	20,565	$44.99	$925,219.35	1,130,309
3/13/2023	Suresh K. Durgam	EVP	Sell	7,344	$45.04	$330,773.76	23,104
3/10/2023	Lawrence J. Hineline	CFO	Sell	15,663	$43.06	$674,448.78
3/10/2023	Mark Neumann	EVP	Sell	8,550	$43.34	$370,557.00	57,357
3/10/2023	Sharon Mates	CEO	Sell	41,770	$43.15	$1,802,375.50	1,130,309
3/1/2023	Mark Neumann	EVP	Sell	7,241	$50.01	$362,122.41	49,199
2/24/2023	Lawrence J. Hineline	CFO	Sell	7,455	$47.03	$350,608.65
2/24/2023	Mark Neumann	EVP	Sell	4,046	$47.12	$190,647.52	56,440
2/24/2023	Sharon Mates	CEO	Sell	22,590	$47.03	$1,062,407.70	1,100,309
2/24/2023	Suresh K. Durgam	SVP	Sell	7,906	$47.14	$372,688.84	23,104
2/21/2023	Lawrence J. Hineline	CFO	Sell	10,443	$46.82	$488,941.26
2/21/2023	Mark Neumann	EVP	Sell	3,898	$47.01	$183,244.98	52,580
2/21/2023	Sharon Mates	CEO	Sell	27,848	$46.83	$1,304,121.84	1,100,309
2/21/2023	Suresh K. Durgam	SVP	Sell	8,354	$46.84	$391,301.36	23,104
2/17/2023	Lawrence J. Hineline	CFO	Sell	53,968	$49.83	$2,689,225.44
12/19/2022	Joel S. Marcus	Director	Sell	5,000	$50.82	$254,100.00	29,233
12/13/2022	Sharon Mates	CEO	Sell	33,083	$55.00	$1,819,565.00	1,100,309
12/1/2022	Michael Halstead	EVP	Sell	50,000	$53.73	$2,686,500.00
9/21/2022	Lawrence J. Hineline	CFO	Sell	65,164	$45.63	$2,973,433.32
8/11/2022	Robert L. Van Nostrand	Director	Sell	30,000	$57.13	$1,713,900.00	9,043
5/12/2022	Joel S. Marcus	Director	Sell	10,000	$55.00	$550,000.00	54,233
4/8/2022	Mark Neumann	EVP	Sell	86,348	$64.37	$5,558,220.76	45,339
3/18/2022	Rory B. Riggs	Director	Sell	20,637	$61.18	$1,262,571.66
3/16/2022	Rory B. Riggs	Director	Sell	64,534	$59.27	$3,824,930.18
3/7/2022	Joel S. Marcus	Director	Sell	5,000	$54.52	$272,600.00
3/4/2022	Suresh K. Durgam	Insider	Sell	3,860	$55.52	$214,307.20
3/2/2022	Suresh K. Durgam	Insider	Sell	4,177	$56.98	$238,005.46
2/24/2022	Lawrence J. Hineline	CFO	Sell	7,454	$51.97	$387,384.38
2/24/2022	Mark Neumann	EVP	Sell	7,906	$52.21	$412,772.26
2/24/2022	Sharon Mates	CEO	Sell	22,589	$51.98	$1,174,176.22
2/24/2022	Suresh K. Durgam	Insider	Sell	4,046	$52.27	$211,484.42
2/22/2022	Lawrence J. Hineline	CFO	Sell	10,443	$55.40	$578,542.20
2/22/2022	Mark Neumann	EVP	Sell	11,139	$55.29	$615,875.31
2/22/2022	Sharon Mates	CEO	Sell	27,847	$55.39	$1,542,445.33
2/22/2022	Suresh K. Durgam	Insider	Sell	4,177	$55.29	$230,946.33
1/18/2022	Suresh K. Durgam	Insider	Sell	6,223	$42.03	$261,552.69
1/10/2022	Lawrence J. Hineline	CFO	Sell	19,639	$40.76	$800,485.64
1/10/2022	Mark Neumann	EVP	Sell	20,948	$40.78	$854,259.44
1/10/2022	Sharon Mates	CEO	Sell	41,896	$40.78	$1,708,518.88
1/10/2022	Suresh K. Durgam	Insider	Sell	6,870	$40.76	$280,021.20
12/21/2021	Lawrence J. Hineline	CFO	Sell	175,000	$47.59	$8,328,250.00
12/21/2021	Michael Halstead	EVP	Sell	176,863	$47.56	$8,411,604.28

The Crypto That’s Making Wall Street Sweat

From Crypto 101 Media | Ad

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

SEC Filings (Institutional Ownership Changes) for Intra-Cellular Therapies (NASDAQ:ITCI)

92.33% of Intra-Cellular Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Intra-Cellular Therapies Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/8/2024	Phocas Financial Corp.	19,233	$1.41M	0.0%	-5.9%	0.018%
11/7/2024	Whalen Wealth Management Inc.	2,996	$0.22M	0.2%	N/A	0.003%
11/7/2024	First Turn Management LLC	254,800	$18.64M	3.0%	-26.6%	0.240%
11/7/2024	LMR Partners LLP	31,177	$2.28M	0.0%	+96.2%	0.029%
11/7/2024	Swiss National Bank	185,500	$13.57M	0.0%	+8.1%	0.175%
11/6/2024	Mutual of America Capital Management LLC	44,091	$3.23M	0.0%	-0.9%	0.042%
11/6/2024	Natixis Advisors LLC	24,583	$1.80M	0.0%	-22.4%	0.023%
11/6/2024	Simplify Asset Management Inc.	30,883	$2.26M	0.1%	+66.6%	0.029%
11/6/2024	CIBC Asset Management Inc	2,806	$0.21M	0.0%	N/A	0.003%
11/6/2024	KBC Group NV	2,864	$0.21M	0.0%	+17.3%	0.003%
11/6/2024	Oppenheimer Asset Management Inc.	38,850	$2.84M	0.0%	+9.5%	0.037%
11/6/2024	MQS Management LLC	3,672	$0.27M	0.2%	N/A	0.003%
11/5/2024	Victory Capital Management Inc.	63,742	$4.66M	0.0%	-6.5%	0.060%
11/5/2024	Aigen Investment Management LP	14,890	$1.09M	0.2%	+91.3%	0.014%
11/5/2024	Prime Capital Investment Advisors LLC	7,420	$0.54M	0.0%	-5.0%	0.007%
11/5/2024	Entropy Technologies LP	7,116	$0.52M	0.1%	N/A	0.007%
11/4/2024	Versor Investments LP	3,509	$0.26M	0.0%	N/A	0.003%
11/4/2024	Lisanti Capital Growth LLC	58,115	$4.25M	1.1%	-29.9%	0.055%
11/4/2024	State of New Jersey Common Pension Fund D	35,673	$2.61M	0.0%	+0.6%	0.034%
11/4/2024	TimesSquare Capital Management LLC	438,083	$32.06M	0.5%	+6.5%	0.413%
11/2/2024	Covestor Ltd	1,811	$0.13M	0.1%	+40.4%	0.002%
11/1/2024	Atria Investments Inc	5,137	$0.38M	0.0%	+41.1%	0.005%
11/1/2024	Assetmark Inc.	2,477	$0.18M	0.0%	+9.1%	0.002%
11/1/2024	Capital Performance Advisors LLP	1,012	$74K	0.0%	N/A	0.001%
11/1/2024	Quantum Private Wealth LLC	38,661	$2.83M	1.0%	+1.0%	0.037%
10/31/2024	Principal Financial Group Inc.	597,713	$43.74M	0.0%	+3.3%	0.566%
10/31/2024	M&G PLC	124,324	$9.08M	0.0%	N/A	0.118%
10/29/2024	Emerald Advisers LLC	441,296	$32.29M	1.3%	+12.4%	0.418%
10/29/2024	Harbor Capital Advisors Inc.	34,974	$2.56M	0.1%	+144.6%	0.033%
10/29/2024	Emerald Mutual Fund Advisers Trust	334,673	$24.49M	1.3%	+6.6%	0.317%
10/28/2024	Oak Ridge Investments LLC	11,391	$0.83M	0.1%	-3.8%	0.011%
10/28/2024	US Bancorp DE	7,951	$0.58M	0.0%	+3.3%	0.008%
10/25/2024	Pinnacle Associates Ltd.	176,124	$12.61M	0.2%	+3.0%	0.167%
10/25/2024	China Universal Asset Management Co. Ltd.	20,323	$1.49M	0.2%	+63.9%	0.019%
10/25/2024	abrdn plc	250,963	$18.36M	0.0%	+7.5%	0.238%
10/25/2024	Pallas Capital Advisors LLC	2,990	$0.23M	0.0%	-27.4%	0.003%
10/24/2024	Nisa Investment Advisors LLC	2,676	$0.20M	0.0%	-35.8%	0.003%
10/24/2024	DekaBank Deutsche Girozentrale	51,997	$3.80M	0.0%	-1.0%	0.049%
10/24/2024	Wealth Enhancement Advisory Services LLC	8,810	$0.65M	0.0%	+185.6%	0.008%
10/24/2024	PFG Investments LLC	3,309	$0.24M	0.0%	-62.9%	0.003%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	3,822	$0.28M	0.0%	+21.3%	0.004%
10/23/2024	Assenagon Asset Management S.A.	232,933	$17.04M	0.0%	-32.1%	0.221%
10/23/2024	Moody Aldrich Partners LLC	91,104	$6.67M	1.2%	-8.0%	0.086%
10/23/2024	Hennion & Walsh Asset Management Inc.	14,942	$1.09M	0.1%	-9.5%	0.014%
10/22/2024	Lecap Asset Management Ltd.	6,815	$0.50M	0.1%	N/A	0.006%
10/21/2024	Cetera Trust Company N.A	2,520	$0.18M	0.1%	+24.8%	0.002%
10/19/2024	Allspring Global Investments Holdings LLC	1,855	$0.14M	0.0%	-97.3%	0.002%
10/18/2024	Raymond James & Associates	158,852	$11.62M	0.0%	+2.8%	0.150%
10/16/2024	nVerses Capital LLC	3,900	$0.29M	0.1%	N/A	0.004%
10/11/2024	Creative Planning	16,188	$1.18M	0.0%	-17.5%	0.015%
10/10/2024	Essex Investment Management Co. LLC	58,385	$4.27M	0.7%	+85.7%	0.055%
10/10/2024	Inspire Investing LLC	5,606	$0.41M	0.0%	+10.4%	0.005%
10/8/2024	CWM LLC	13,274	$0.97M	0.0%	+867.5%	0.013%
10/5/2024	Handelsbanken Fonder AB	26,300	$1.92M	0.0%	+23.5%	0.025%
10/3/2024	Park Avenue Securities LLC	5,190	$0.38M	0.0%	-11.7%	0.005%
10/3/2024	SG Americas Securities LLC	4,244	$0.31M	0.0%	-91.3%	0.004%
9/4/2024	Ghisallo Capital Management LLC	50,000	$3.42M	0.2%	N/A	0.047%
8/27/2024	Clearbridge Investments LLC	1,721,610	$117.91M	0.1%	-1.3%	1.631%
8/21/2024	Truist Financial Corp	45,435	$3.11M	0.0%	-29.4%	0.043%
8/16/2024	Perceptive Advisors LLC	1,716,407	$117.56M	2.8%	+62.6%	1.626%
8/16/2024	Quarry LP	500	$34K	0.0%	-66.7%	0.000%
8/16/2024	Creative Planning	19,611	$1.34M	0.0%	+45.9%	0.019%
8/16/2024	Algert Global LLC	66,340	$4.54M	0.2%	-49.2%	0.063%
8/16/2024	Driehaus Capital Management LLC	215,439	$14.76M	0.1%	N/A	0.204%
8/15/2024	Susquehanna Fundamental Investments LLC	17,108	$1.17M	0.0%	N/A	0.016%
8/15/2024	Scientech Research LLC	35,270	$2.42M	0.5%	N/A	0.033%
8/15/2024	Mackenzie Financial Corp	4,919	$0.34M	0.0%	-32.9%	0.005%
8/15/2024	The Manufacturers Life Insurance Company	21,774	$1.49M	0.0%	-58.9%	0.021%
8/15/2024	Millennium Management LLC	889,102	$60.90M	0.0%	+214.5%	0.842%
8/15/2024	D. E. Shaw & Co. Inc.	580,359	$39.75M	0.0%	+48.7%	0.550%
8/15/2024	AQR Capital Management LLC	105,431	$7.22M	0.0%	+33.5%	0.100%
8/15/2024	Point72 Europe London LLP	32,300	$2.21M	0.2%	N/A	0.031%
8/15/2024	Point72 Hong Kong Ltd	44,368	$3.04M	0.2%	N/A	0.042%
8/14/2024	Squarepoint Ops LLC	261,633	$17.92M	0.0%	+110.7%	0.248%
8/14/2024	Fred Alger Management LLC	16,564	$1.13M	0.0%	+32.2%	0.016%
8/14/2024	Point72 Asset Management L.P.	554,186	$37.96M	0.1%	+218.9%	0.524%
8/14/2024	Cubist Systematic Strategies LLC	95,071	$6.51M	0.0%	+147.6%	0.090%
8/14/2024	Point72 DIFC Ltd	20,385	$1.40M	0.0%	N/A	0.019%
8/14/2024	Marshall Wace LLP	499,015	$34.18M	0.0%	N/A	0.473%
8/14/2024	Xponance Inc.	13,329	$0.91M	0.0%	+135.6%	0.013%
8/14/2024	Bank of Montreal Can	292,975	$21.23M	0.0%	-12.1%	0.278%
8/14/2024	Lombard Odier Asset Management Europe Ltd	60,000	$4.11M	0.2%	N/A	0.057%
8/14/2024	Integral Health Asset Management LLC	145,000	$9.93M	0.9%	+16.0%	0.137%
8/14/2024	Hood River Capital Management LLC	487,518	$33.39M	0.7%	N/A	0.462%
8/14/2024	Avoro Capital Advisors LLC	3,000,000	$205.47M	2.7%	+21.2%	2.842%
8/14/2024	ProShare Advisors LLC	19,965	$1.37M	0.0%	-15.5%	0.019%
8/14/2024	Profund Advisors LLC	6,678	$0.46M	0.0%	-39.7%	0.006%
8/13/2024	Ensign Peak Advisors Inc	41,637	$2.85M	0.0%	-70.6%	0.039%
8/13/2024	Sei Investments Co.	160,487	$10.99M	0.0%	+25.1%	0.152%
8/13/2024	Skandinaviska Enskilda Banken AB publ	259,121	$17.74M	0.1%	+99.0%	0.245%
8/13/2024	DCF Advisers LLC	100,507	$6.88M	3.5%	+3.8%	0.095%
8/13/2024	Simplify Asset Management Inc.	18,537	$1.27M	0.1%	N/A	0.018%
8/13/2024	Canada Pension Plan Investment Board	146,200	$10.01M	0.0%	-4.1%	0.138%
8/13/2024	Public Employees Retirement Association of Colorado	10,057	$0.69M	0.0%	-2.9%	0.010%
8/12/2024	XTX Topco Ltd	20,220	$1.39M	0.1%	N/A	0.019%
8/12/2024	Seven Eight Capital LP	21,910	$1.50M	0.2%	N/A	0.021%
8/12/2024	Hsbc Holdings PLC	13,986	$0.96M	0.0%	-47.6%	0.013%
8/12/2024	Vanguard Personalized Indexing Management LLC	6,312	$0.43M	0.0%	+20.0%	0.006%
8/12/2024	Amalgamated Bank	6,922	$0.47M	0.0%	+117.3%	0.007%
8/10/2024	Mutual of America Capital Management LLC	44,504	$3.05M	0.0%	-4.2%	0.042%

Data available starting January 2016

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $90.51

$89.41

$91.68

50 Day Range

MA: $76.42

$71.19

$90.51

52 Week Range

Now: $90.51

$52.88

$91.68

Volume

586,499 shs

Average Volume

867,119 shs

Market Capitalization

$9.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Who are the company insiders with the largest holdings of Intra-Cellular Therapies?: Intra-Cellular Therapies' top insider shareholders include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Suresh K Durgam (SVP)
Nostrand Robert L Van (Director)
Suresh K Durgam (EVP)
Learn More about top insider investors at Intra-Cellular Therapies.
Who are the major institutional investors of Intra-Cellular Therapies?: Intra-Cellular Therapies' top institutional shareholders include:
Principal Financial Group Inc. — 0.57%
Emerald Advisers LLC — 0.42%
TimesSquare Capital Management LLC — 0.41%
Emerald Mutual Fund Advisers Trust — 0.32%
First Turn Management LLC — 0.24%
abrdn plc — 0.24%
Learn More about top institutional investors of Intra-Cellular Therapies stock.
Which institutional investors are selling Intra-Cellular Therapies stock?: In the previous quarter, ITCI stock was sold by these institutional investors:
Assenagon Asset Management S.A.
First Turn Management LLC
Allspring Global Investments Holdings LLC
SG Americas Securities LLC
Lisanti Capital Growth LLC
Moody Aldrich Partners LLC
Natixis Advisors LLC
PFG Investments LLC
During the last year, company insiders that have sold Intra-Cellular Therapies company stock include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Suresh K Durgam (SVP)
Nostrand Robert L Van (Director)
Learn More investors selling Intra-Cellular Therapies stock.
Which institutional investors are buying Intra-Cellular Therapies stock?: During the last quarter, ITCI stock was acquired by institutional investors including:
M&G PLC
Emerald Advisers LLC
Essex Investment Management Co. LLC
TimesSquare Capital Management LLC
Harbor Capital Advisors Inc.
Emerald Mutual Fund Advisers Trust
Principal Financial Group Inc.
abrdn plc